anti mouse pd1 (Bio X Cell)
Bio X Cell is a verified supplier 
Bio X Cell manufactures this product 
99
Structured Review
Bio X Cell
anti mouse pd1
Anti Mouse Pd1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1248 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+pd1/InVivoMAb+anti-mouse+PD-1/pm41932811-45-0-8
Average 99 stars, based on 1248 article reviews
Anti Mouse Pd1, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 99/100, based on 1248 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/anti+mouse+pd1/InVivoMAb+anti-mouse+PD-1/pm41932811-45-0-8
Average 99 stars, based on 1248 article reviews
anti mouse pd1 - by Bioz Stars,
2026-09
99/100 stars
Images
Related Articles
Injection:Article Title: Quantitative dynamic granzyme B PET imaging to characterize novel combination immunotherapy response in preclinical glioblastoma models Article Snippet: .. Combination immunotherapy mice received an intratumoral injection of M002 (1 × 10 7 pfu/ 5 ul) on day 0, followed two intraperitoneal doses of Article Title: Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer Article Snippet: Anti-mouse CSF1R (BioXCell, clone AFS98) or vehicle control (phosphate-buffered saline, Fresenius Kabi) treatment was started at the same day as tumor cell injection and administered 3x week intraperitoneally for 21 days, 400 μg/injection. .. Article Title: Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction. Article Snippet: .. Paclitaxel (Hengrui, 10 mg/kg), EZH2i (Tazemetostat, MedChemExpress, 20 mg/kg), DPP4i (Trelagliptin, MedChemExpress, 1 mg/kg), ADAM10/17i (TAPI-1, MedChemExpress, 8 mg/kg) and Article Title: Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction Article Snippet: .. Paclitaxel (Hengrui, 10 mg/kg), EZH2i (Tazemetostat, MedChemExpress, 20 mg/kg), DPP4i (Trelagliptin, MedChemExpress, 1 mg/kg), ADAM10/17i (TAPI-1, MedChemExpress, 8 mg/kg) and Article Title: Coronavirus vaccine compositions and methods Article Snippet: .. For a group with combination treatment of In Vivo:Article Title: Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy Article Snippet: In vivo CD8 + T cell depletion: anti-mouse CD8 (BE0061, BioXcell), and anti-rat IgG2b isotype control (BE0090, BioXcell). .. In vivo anti-PD1 treatment: Article Title: Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy. Article Snippet: In vivo CD8+ T cell depletion: anti-mouse CD8 (BE0061, BioXcell), and anti-rat IgG2b isotype control (BE0090, BioXcell). .. In vivo anti-PD1 treatment: Control:Article Title: Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy Article Snippet: In vivo CD8 + T cell depletion: anti-mouse CD8 (BE0061, BioXcell), and anti-rat IgG2b isotype control (BE0090, BioXcell). .. In vivo anti-PD1 treatment: Article Title: Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer Article Snippet: Anti-mouse CSF1R (BioXCell, clone AFS98) or vehicle control (phosphate-buffered saline, Fresenius Kabi) treatment was started at the same day as tumor cell injection and administered 3x week intraperitoneally for 21 days, 400 μg/injection. .. Article Title: Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. Article Snippet: PaB670129 was synthesized according to US20180305450A1 by RD- Biotech. .. Article Title: Decorin facilitates T cell-mediated antitumor immunity and augments the efficacy of anti-PD1 immunotherapy. Article Snippet: In vivo CD8+ T cell depletion: anti-mouse CD8 (BE0061, BioXcell), and anti-rat IgG2b isotype control (BE0090, BioXcell). .. In vivo anti-PD1 treatment: Saline:Article Title: Peritoneal resident macrophages constitute an immunosuppressive environment in peritoneal metastasized colorectal cancer Article Snippet: Anti-mouse CSF1R (BioXCell, clone AFS98) or vehicle control (phosphate-buffered saline, Fresenius Kabi) treatment was started at the same day as tumor cell injection and administered 3x week intraperitoneally for 21 days, 400 μg/injection. .. Synthesized:Article Title: Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. Article Snippet: PaB670129 was synthesized according to US20180305450A1 by RD- Biotech. .. |
![(A) Left, confocal images of h Shp2 WT (green) mixed with the indicated h PD1 ICD (magenta) in LLPS buffer. Right, the OD 600 values of the indicated h Shp2: h PD1 ICD mixture. [Shp2] = [PD1 ICD ] = 8 μM. n = 3 independent experiments. (B) Time-lapse bright field and confocal images showing a condensate fusion event in a mixture of 8 μM h Shp2 WT (green) and 8 μM p- h PD1 ICD (magenta). Time zero marks the start of image acquisition. (C) Left, time-lapse confocal images showing FRAP of h Shp2 WT (green) and h PD1 ICD (magenta) within the indicated condensate, which was photo-bleached at time zero. Right, FI time courses in the bleached area. FI values were normalized to those of a non-bleached h Shp2:p- h PD1 ICD condensate. [Shp2] = [pPD1 ICD ] = 8 μM. n = 3 condensates. Scale bars: 5 μm (A, C) or 1 μm (B, C inset). Data are mean ± SD. ***P < 0.001; student’s t-test.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F3.large.jpg)
![(A) Representative confocal images of h Shp2 C459E (green) mixed with either non-phosphorylated h PD1ICD or p- h PD1ICD (magenta). [Shp2] = [PD1 ICD ] = 8 μM. (B) Representative time-lapse confocal images of h Shp2:p- h PD1condensates containing the indicated Shp2 variant. Condensates were photo-bleached at time zero. [Shp2] = [PD1 ICD ] = 8 μM. (C) Time courses of Shp2 (left) or PD1 ICD (right) FI of the photo-bleached area in B. FIs were normalized to a non-bleached PD1:Shp2 condensates nearby. n = 3 condensates. Scale bars: 5 μm (A) or 1 μm (B). Data are mean ± SD.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F4.large.jpg)
![(A) Cartoon depicting a model in which pPD1 induces a close-to-open conformational transition in Shp2. The basic amino acids that mediate Shp2 self-association (R362/K364) are highlighted as “+”. (B) Spot matrix plots showing the OD 600 for h Shp2 WT mixed with either h PD1 ICD or p- h PD1 ICD across varying concentrations of Shp2 and NaCl. [PD1 ICD ] = 8 μM. From left to right, [Shp2] were 0, 2, 4, 8, 12 μM, from top to bottom [NaCl] were 75, 125, 200, 400, and 600 mM. (C) Confocal images of condensates formed by Shp2 WT and p- h PD1 ICD in LLPS buffer containing the indicated [NaCl]. (D) Time courses for the OD 600 of Shp2 WT :p- h PD1 ICD mixture before and after changes in [NaCl] upon injection of NaCl-containing LLPS buffer. [Shp2] = [PD1 ICD ] = 8 μM. (E) Effect of Shp2 REKE mutations on h PD1: h Shp2 LLPS. Left, OD 600 of h Shp2 WT or h Shp2 REKE mixed with indicated [p- h PD1 ICD ]. Right, representative confocal images of the condensates in h PD1: h Shp2 WT mixture and h PD1: h Shp2 REKE mixture containing 8 μM of each. n = 3 independent experiments. (F) Same as E except that m Shp2 variants were used. n = 3 independent experiments. Scale bars: 5 μm. Data are mean ± SD.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F5.large.jpg)
![(A) Schematic depicting a Shp2 catalytic activity assay, where recombinant h Shp2 was incubated with p- h PD1 ICD to induce the open conformation. Shp2 mediated dephosphorylation of the substrate DiFMUP produces the fluorescent DiFMU. (B) Representative time course of [DiFMU] upon mixing with the indicated Shp2 variants. To prevent PD1:Shp2 LLPS, [ h Shp2] and [p- h PD1 ICD ] were kept at 20 nM and 30 nM, respectively. (C) Initial velocity (V0) of [DiFMU] increase plotted against [DiFMUP] for the indicated Shp2 variants, fitted by the Michaelis-Menten model. n = 3 independent experiments. (D) Dot plots summarizing K M and k cat values calculated from C. n = 3 independent experiments. (E) Same as A, except that pre-phosphorylated h CD3ζ (p- h CD3ζ) was used as a substrate. (F) Representative IB showing the time-course of phosphorylation status of h CD3ζ upon mixing with 4 μM p- h PD1 ICD and 0.4 μM h Shp2 WT or h Shp2 REKE . (G) Same as F, except that h CD3ζ was mixed with 4 μM p- h PD1 ICD and 4 μM h Shp2 WT or h Shp2 REKE . (H) Time course of % p- h CD3ζ-GFP calculated from F (left) or G (right). n = 3 independent experiments. (I) Left, representative confocal images of h Shp2 WT (orange) and GFP(0)-tagged proteins (green) mixed with p- h PD1 (magenta) under the LLPS condition. Right, violin plots summarizing the GFP enrichment in the Shp2 condensates shown on the left. n = 5 independent experiments. (J) Left, representative confocal images of synaptic PLA signals (magenta) and bright field signals (grey) of Jurkat cells co-expressing V5-tagged h PD1 and the indicated ALFA-tagged receptors and h Shp2 variants. Right, violin plots summarizing the number of PLA puncta in individual cells shown on the left. n = 118-171 cells. (K) Model depicting how PD1:Shp2 LLPS organizes the inhibitory signalosome. PD1 phosphorylation promotes Shp2 condensation into dynamic LLPS compartments that enhance PD1 clustering, maintain liquidity through catalysis, and achieve selective substrate inclusion (CD3ζ/CD28) and exclusion (TIGIT). Scale bars: 2 μm (I) or 10 μm (J). Data are mean ± SD. *P < 0.05; ***P < 0.001; ns, not significant; student’s t-test.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F6.large.jpg)
![(A) Schematic depicting a Shp2 catalytic activity assay, where recombinant h Shp2 was incubated with p- h PD1 ICD to induce the open conformation. Shp2 mediated dephosphorylation of the substrate DiFMUP produces the fluorescent DiFMU. (B) Representative time course of DiFMU FI upon mixing with 20 nM h Shp2 WT and the varying concentrations of [p- h PD1 ICD ]. (C) Initial velocity (V0) of DiFMU FI increase plotted against [p- h PD1 ICD ] calculated from B.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F9.large.jpg)
![(A) Schematic depicting a Jurkat cell expressing h PD1-GFP with either mCherry- h Shp2 WT or h Shp2 REKE , cocultured with SEE-loaded, h PDL1-expressing, CD80 KO Raji cells. (B) Left, IL-2 secreted in the Jurkat:Raji coculture shown in a in the presence or absence of α- h PDL1. Right, % inhibition of IL-2 secretion mediated by the indicated h PD1 variant calculated from the left. [SEE] = 0.06 ng/mL. n = 3 independent experiments. Data are mean ± SD. ***P < 0.001; student’s t-test.](https://bio-rxiv-images-cdn.bioz.com/dois_ending_with_29/10__64898_slash_2026__03__09__710629/10__64898_slash_2026__03__09__710629___F12.large.jpg)
